CD9 is an unreliable antibody for bone marrow purging
Progress in Clinical and Biological Research
|January 1, 1990
Summary
This study evaluated monoclonal antibodies for bone marrow purging. CD10 and CD19 are reliable markers for pre-B cells, unlike CD9, which can affect non-target cells.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Autologous bone marrow transplantation (ABMT) requires purging of pre-B lineage contamination.
- Monoclonal antibodies (mAbs) are used with various methods for purging, including complement, magnetic microspheres, and phototherapy.
- A common mAb cocktail includes CD9, CD10, and CD19, targeting antigens on pre-B lymphocytes.
Purpose of the Study:
- To assess the reliability of CD9, CD10, and CD19 expression for pre-B cell purging in ABMT.
- To determine the correlation between antigen expression and disease status in patients undergoing ABMT.
Main Methods:
- Analysis of CD9, CD10, and CD19 antigen expression on pre-B lymphocytes.
- Correlation of antigen expression levels with disease status (remission vs. relapse).
- Evaluation of CD9 antigen presence on non-target cell populations like megakaryocytes and platelets.
Main Results:
- CD10 and CD19 expression levels correlate with disease status, showing lower positivity in remission and higher positivity in relapse.
- CD9 expression is inconsistent and varies independently of disease status.
- CD9 is also expressed on megakaryocytes, platelets, and mature granulocytes, indicating potential off-target effects.
Conclusions:
- CD10 and CD19 are more reliable markers than CD9 for pre-B cell purging in ABMT.
- The use of CD9 in purging protocols may lead to the unintended removal of essential non-malignant cell populations.
- Refined purging strategies should focus on CD10 and CD19 for improved specificity and efficacy in ABMT.
